Because CGs are a class of numerous natural compounds with anti-tumor activity [13], here we sought to understand both if other CGs could represent additional treatment options for ERα-positive BC treatment to be administered alone or in combination with other anti-BC drugs, and if the Na/K ATPase could be considered a biomarker for addressing CG treatment in women carrying ERα-positive BC. The gene discussed is ESR1; the disease is breast cancer.